文献速递眼底病与葡萄膜炎

Abicipar治疗新生血管性年龄相关性黄斑变性的3期随机对照研究两年结果

Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration.
PubMed 文献 · Ophthalmology · 2020-11-19

两项多中心3期试验(CEDAR和SEQUOIA)汇总分析1888例初治nAMD患者,比较abicipar每8周和每12周方案与雷珠单抗每月方案的2年疗效与安全性。完成研究的患者中,abicipar疗效维持至104周,但眼内炎症不良事件发生率高于雷珠单抗。

要点

  • abicipar每8周和每12周方案在104周时维持稳定视力比例分别为93.0%和89.8%。
  • abicipar组眼内炎症不良事件总体发生率约15%–17.6%,远高于雷珠单抗组1.3%。
  • 第二年abicipar眼内炎症新发事件大幅减少,与雷珠单抗相当。

核心结论

  • 两年结果显示abicipar每8周和每12周方案在nAMD中维持疗效,但眼内炎症不良事件发生率高于雷珠单抗。
  • 第二年abicipar眼内炎症新发事件大幅减少,与雷珠单抗相当。

研究设计与样本

  • 两项方案相同的多中心随机3期临床试验(CEDAR和SEQUOIA),汇总数据分析。
  • 共纳入1888例活动性脉络膜新生血管继发于AMD且BCVA为24–73个ETDRS字母的初治患者(每例1眼)。
  • 患者随机分为abicipar 2 mg每8周组(n=630)、abicipar 2 mg每12周组(n=628)和雷珠单抗0.5 mg每4周组(n=630)。

主要发现

  • 完成研究的患者中,第104周稳定视力(BCVA较基线丢失<15字母)比例分别为93.0%(396/426)、89.8%(379/422)和94.4%(470/498)。
  • 第104周BCVA较基线平均变化分别为+7.8字母、+6.1字母和+8.5字母。
  • 第104周中央视网膜厚度较基线平均变化分别为-147 μm、-146 μm和-142 μm。
  • 基线至第52周眼内炎症不良事件总体发生率分别为15.4%、15.3%和0.3%;至第104周分别为16.2%、17.6%和1.3%。

关键数值与推荐

  • abicipar每8周组104周共14次注射,每12周组共10次注射,雷珠单抗每4周组共25次注射。
  • 第二年abicipar眼内炎症新发事件发生率分别为0.8%和2.3%,雷珠单抗为1.0%。

临床怎么用

  • abicipar每8周或每12周方案可延长给药间隔、减少治疗负担。
  • 使用abicipar需关注眼内炎症不良事件,尤其第一年发生率较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the 2-year efficacy and safety of abicipar every 8 weeks and quarterly (after initial doses) compared with monthly ranibizumab in patients with treatment-naïve neovascular age-related macular degeneration (nAMD). DESIGN: Two multicenter, randomized, phase 3 clinical trials with identical protocols (CEDAR and SEQUOIA). Analyses used pooled trial data. PARTICIPANTS: The trials enrolled 1888 patients (1 eye/patient) with active choroidal neovascularization secondary to age-related macular degeneration and best-corrected visual acuity (BCVA) of 24 to 73 Early Treatment Diabetic Retinopathy Study letters. METHODS: At enrollment, patients were assigned to study eye treatment with abicipar 2 mg every 8 weeks after initial doses at baseline and weeks 4 and 8 (abicipar Q8, n = 630), abicipar 2 mg every 12 weeks after initial doses at baseline and weeks 4 and 12 (abicipar Q12, n = 628), or ranibizumab 0.5 mg every 4 weeks (ranibizumab Q4, n = 630). MAIN OUTCOME MEASURES: Efficacy measures included stable vision (<15-letter loss in BCVA from baseline) and change from baseline in BCVA and central retinal thickness (CRT). Safety measures included adverse events (AEs). RESULTS: For patients who completed the study, efficacy of abicipar after initial doses was maintained through week 104. At week 104, the proportion of patients with stable vision was 93.0% (396/426), 89.8% (379/422), and 94.4% (470/498); mean change in BCVA from baseline was +7.8 letters, +6.1 letters, and +8.5 letters, and mean change in CRT from baseline was -147 μm, -146 μm, and -142 μm in the abicipar Q8 (14 injections), abicipar Q12 (10 injections), and ranibizumab Q4 (25 injections) groups, respectively. The overall incidence of intraocular inflammation (IOI) AEs was 15.4%, 15.3%, and 0.3% from baseline through week 52 and 16.2%, 17.6%, and 1.3% from baseline through week 104 in the abicipar Q8, abicipar Q12, and ranibizumab Q4 groups, respectively. CONCLUSIONS: Two-year results show efficacy of abicipar Q8 and Q12 in nAMD. First onset of IOI events with abicipar was much reduced in the second year and comparable with ranibizumab (0.8% and 2.3% vs. 1.0%). The extended duration of effect of abicipar allows for quarterly dosing and reduced treatment burden.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Khurana RN, Kunimoto D, Yoon YH, et al. Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration. Ophthalmology. 2020. PMID: 33221326. doi:10.1016/j.ophtha.2020.11.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。